This is a competing renewal for the new Johns Hopkins University CFAR, initially funded in 2012. The new CFAR had a complete change in leadership, a major reorganization, a number of new and highly innovative approaches, and the enthusiastic and vigorous participation and support of the entire JHU HIV research community and the institution's leaders, who have contributed $2.25 million of additional support to fund additional developmental awards, student engagement, and outreach activities. For the past 4 years the CFAR has reinvigorated the HIV community at JHU, built thriving platforms through which interdisciplinary collaboration occurs, engaged new and junior investigators in cutting-edge research activities, provided vitally needed developmental resources for conducting pilot studies that lead to extramural funding, and contributed to the recruitment of new faculty, particularly 6 members of underrepresented minority groups. The CFAR has served over 373 HIV investigators, >130 NIH grants, and provided mentoring and assistance to 212 early stage investigators. Developmental Awards to early stage investigators or those new to HIV research have resulted in $57 million in new extramural awards, and our Internal Scientific Reviews of NIH applications have contributed to the funding of 14 new R01 or similar grants. The overall goal of this competing renewal application is to continue and enhance the ability of the Johns Hopkins University CFAR to nurture and support high-impact HIV research and researchers across a broad range of disciplines and specialties in the multiple divisions of this major research university.
Our specific aims are 1) to enhance the integration and productivity of HIV/AIDS research by promoting inter-disciplinary innovation and collaboration; 2) to provide mentoring, support, and pilot funding for the next generation of HIV/AIDS researchers, with a commitment to recruiting researchers from underrepresented minority groups; 3) to support HIV/AIDS researchers with direct services to assist with recruitment of clinical research participants, performance of laboratory assays, design and analysis of research studies, and training in research methodologies; and 4) to mobilize and coordinate capacity from across JHU to combat the HIV epidemic in Baltimore through engagement, training, outreach, and evaluation of community-based intervention studies. The CFAR has 6 Cores and 3 Scientific Working Groups that provide services and support innovation in high-priority HIV research. The Baltimore HIV Collaboratory, and its Plan Baltimore 2020 project coordinate the JHU response to the local epidemic, orchestrating HIV research and outreach activities, and expanding the pipeline of future HIV researchers through the Baltimore HIV Scholars Program and Generation Tomorrow, initiatives aimed at students. The Provost and Deans of the 3 health professions schools at JHU have committed institutional funds of $2.7 million to support pilot awards, student recruitment, and Baltimore engagement. The CFAR will continue to have a galvanizing and transformative impact on HIV/AIDS research at JHU and we are delighted to submit this renewal application.

Public Health Relevance

The overall goal of this application is to continue and enhance the ability of the Johns Hopkins University CFAR to nurture and support high-impact HIV research and researchers across a broad range of disciplines and specialties in the multiple divisions of this major research university. The CFAR will recruit, mentor and support new investigators, including members of underrepresented minority groups, provide research support services, and leverage the capacity of Johns Hopkins to help address the Baltimore HIV epidemic.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Dean, Lorraine T; Nicholas, Lauren Hersch (2018) Using Credit Scores to Understand Predictors and Consequences of Disease. Am J Public Health 108:1503-1505
Smith, M Kumi; Graham, Matthew; Latkin, Carl A et al. (2018) Using Contact Patterns to Inform HIV Interventions in Persons Who Inject Drugs in Northern Vietnam. J Acquir Immune Defic Syndr 78:1-8
Canan, Chelsea E; Chander, Geetanjali; Monroe, Anne K et al. (2018) High-Risk Prescription Opioid Use Among People Living With HIV. J Acquir Immune Defic Syndr 78:283-290
Levinson, Kimberly L; Riedel, David J; Ojalvo, Laureen S et al. (2018) Gynecologic cancer in HIV-infected women: treatment and outcomes in a multi-institutional cohort. AIDS 32:171-177
Grover, Surbhi; Desir, Fidel; Jing, Yuezhou et al. (2018) Reduced Cancer Survival Among Adults With HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis. J Acquir Immune Defic Syndr 79:421-429
Sturgeon, Kathleen M; Hackley, Renata; Fornash, Anna et al. (2018) Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema. Cancer 124:95-104
Mwinnyaa, George; Gray, Ronald H; Grabowski, Mary K et al. (2018) Brief Report: Age-Disparate Relationships and HIV Prevalence Among Never Married Women in Rakai, Uganda. J Acquir Immune Defic Syndr 79:430-434
Riddler, Sharon A; Zheng, Lu; Durand, Christine M et al. (2018) Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infect Dis 5:ofy242
Dean, Lorraine T; Moss, Shadiya L; Ransome, Yusuf et al. (2018) ""It still affects our economic situation"": long-term economic burden of breast cancer and lymphedema. Support Care Cancer :
Solomon, S S; Sulkowski, M S; Amrose, P et al. (2018) Directly observed therapy of sofosbuvir/ribavirin +/- peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT). J Viral Hepat 25:37-46

Showing the most recent 10 out of 724 publications